(Q86243264)
Statements
A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis (English)
0 references
August 2007
0 references
October 2010
0 references
1,065
0 references
18 year
0 references